



[Science](#)[Education](#)[Patient Care](#)

[Our Society](#)[Our Mission, Vision & Values](#)[EBMT Membership 2025](#)[Organisational Structure 2025](#)[Financial Highlights 2025](#)[EBMT Partners](#)

## Breadcrumb

1. [Home](#)

# Entity Print

## Accelerating development and improving access to CAR and TCR-engineered T cell therapy (T2Evolve)

**Programme:** Innovative Medicines Initiative

**Duration:** 2021-2025

**Total budget:** € 19,3M

**Brief description:** The aim of T2EVOLVE is to develop an innovation ecosystem to accelerate the development of engineered T cell therapies in the EU. The project seeks to develop tools and markers to predict therapy efficacy and toxicity, along with standardised methods for production and monitoring. It also aims to enhance patient involvement and provide educational tools to improve communication with healthcare providers.

**EBMT role:** Collaboration in Data Harmonization project to support the development of a harmonised European parameter set and core data structure for the evaluation of CAR T-Cell therapies (CART-CD).

**2025 update:** Within the CART-CD project, EBMT collaborated with consortium partners on the design and conduct of two Delphi surveys and later analysis of outcomes to support expert consensus building.

**Project website:** <https://t2evolve.com/>

## Oncode Accelerator

**Programme:** Dutch National Growth Fund

**Duration:** 2022-2032

**Total budget:** € 89M (Cell & Gene Therapy Workstream)

**Brief description:** Oncode Accelerator is a collaboration of more than 35 public and private partners. Together, the consortium leverages the full potential of the Dutch innovation ecosystem by building development pipelines for four of the most common types of cancer therapies: Small Molecules, Biologics, Cell and Gene Therapies, and Therapeutic Vaccines.

**EBMT role:** Second-tier beneficiary and contributor in Cell and Gene Therapy workstream, led by NKI and UMCU. Providing relevant, fully anonymized CAR T data. Alignment and Upload of Dutch CAR T data into the EBMT Registry. Creation of a new Dutch module in the EBMT Registry.

**2025 update:** Ongoing alignment with the Dutch registry for legal framework establishment. Dutch module item selection being discussed within the project's clinical and production activities task force. Preparation of the Registry infrastructure for the Dutch module development and integration.

**Project website:** <https://www.oncodeaccelerator.nl/>

# European Transplant and Cellular Therapy Online Registry (EuroTraCTOR)

**Programme:** EU4Health

**Duration:** 2022-2025

**Total budget:** € 3,3M

**Brief description:** The grant co-funded the development and implementation of a new EBMT Registry to improve the processes of collecting and using data across EU health systems. This included the design, development and rollout of new versions of the Registry, pilot integration exercises with hospital IT systems and stakeholder training. The grant consortium consisted of 11 stakeholders, varying from EBMT member hospitals to national registries and Competent Authorities.

**EBMT role:** project and consortium lead, main beneficiary and responsible for the new Registry deployment.

**2025 update:** In 2025, the project progressed with the test version development of a tool to facilitate data extraction for imports into the EBMT Registry, which was trialled by two consortium hospitals participating in the pilot. The tool is publicly available to everyone for further testing through the following link: [HLA Automated Doc Processor](#).

The year also included the organisation of two consortium coordination workshops, the submission of all remaining project milestones and deliverables and the successful closure of the grant.

**Project website:** <https://www.ebmt.org/registry/eurotractor>

## A Cellular Immunotherapy Virtual Twin for Personalised Cancer Treatment (CERTAINTY)

**Programme:** Horizon Europe

**Duration:** 2024-2028

**Total budget:** € 10M

**Brief description:** The project aims to design, develop and implement a virtual twin system to support CAR T cell therapy for multiple myeloma (MM). This involves using advanced computational models and real patient data to build digital replicas that reflect individual health conditions and help guide treatment decisions. The project focuses on making CAR T therapies more personalised and accessible across health systems by improving how insights from patient data are used in clinical practice.

**EBMT role:** Data provision: facilitating Federated Learning (FL) analyses on CAR-T registry data while fully preserving data confidentiality. Statistical input and work with AI for development of prediction models for MM.

**2025 update:** EBMT initiated the setup of the FL infrastructure, establishing the foundation for secure, distributed analysis of clinical data that remains on-site. Following alignment with consortium partners, an initial dataset of interest was identified and will be further reviewed and refined in 2026. In parallel, efforts to standardise and map the data into the OMOP framework continued, supporting future integration and analysis through the FL system.

**Project website:** <https://www.certainty-virtualtwin.eu>

## **Easy Workflow Integration for Gene Therapy (EASYGEN)**

**Programme:** Innovative Health Initiative

**Duration:** 2025-2030

**Total budget:** € 12,2M

**Brief description:** The aim of the project is to demonstrate a holistic implementation of a user-centric cell and gene therapy point-of-care platform to optimize hospital workflows in cancer treatment. EASYGEN will develop a fully automated, hospital-based platform capable of manufacturing personalised CAR-T

cell therapies within a few days.

**EBMT role:** Collection of scientific expertise from healthcare professionals on the current delivery process and inputs for process optimization. In parallel, a literature review and engagement with patient advocacy groups will be undertaken to scope the potential impact of the EASYGEN solution on patient quality of life.

**2025 update:** The project started in April with the establishment of the project team. Initial engagement with the Patient Advocacy Committee was initiated, alongside early scoping and brainstorming to define the focus areas for the upcoming literature review. Co-development of the communication plan is ongoing.

**Project website:** <https://www.easygen-consortium.eu/>